Human parvovirus B19‐associated encephalopathy with hereditary spherocytosis

Abstract

1 Kon e-Paut I, Shahram F, Darce-bello M et al. Consensus classification criteria for paediatric Behc et’s disease from a prospective observational cohort: PEDBD. Ann. Rheum. Dis. 2016; 75: 958–64. 2 Seyahi E. Behc et’s disease: How to diagnose and treat vascular involvement. Best Pract. Res. Clin. Rheumatol. 2016; 30: 279–95. 3 Sato T, Takagawa T, Kakuta Y et al. NUDT15, FTO, and RUNX1 genetic variants and thiopurine intolerance among Japanese patients with inflammatory bowel diseases. Intest. Res. 2017; 15: 328–37. 4 Viswanathan V, Murray KJ. Management of children with juvenile idiopathic arthritis. Indian J. Pediatr. 2016; 83: 63–70. 5 Shugaiv E, T€uz€un E, Mutlu M, Kiyat-Atamer A, Kurtuncu M, Akman-Demir G. Mycophenolate mofetil as a novel immunosuppressant in the treatment of neuro-Behc et’s disease with parenchymal involvement: Presentation of four cases. Clin. Exp. Rheumatol. 2011; 29: S64–7. 6 Groot N, de Graeff N, Marks SD et al. European evidencebased recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative. Ann. Rheum. Dis. 2017; 76: 1965–73. 7 Li S, Yang H, Guo P et al. Efficacy and safety of immunosuppressive medications for steroid-resistant nephrotic syndrome in children: A systematic review and network metaanalysis. Oncotarget 2017; 8: 73050–62.